{
  "id": "cluster_0_docid2",
  "content": "Genovel Biocare's Q3 provider report notes an unprecedented 89% success rate in stage III melanoma patients using combination immunotherapy. The Rome facility reported 12 cases requiring extended hospital stays, including patient PAT-88734ZL who developed cytokine release syndrome. Dr. Valtierra's cases accounted for 40% of all advanced therapy claims.",
  "metadata": {
    "format": "provider_report"
  }
}